RxDoctor Payments Data

Robert Ballard, MD

Sleep Medicine · Littleton, CONPI 1255424347

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,377 and has fallen 91.0% since, to $124 in 2025.

$2,930in general payments, 2019–2025

Across 169 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$501
  • AstraZeneca$469
  • Boehringer Ingelheim$449
  • GSK$334
  • Grifols USA, LLC$212
  • United Therapeutics Corporation$107
  • plus $860 from 21 others

What the payments were for

  • Food & beverage$2,78595%
  • Education$1455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,930 in reported general payments places this provider in the 80th percentile of 35 sleep medicine providers in Colorado.

See all sleep medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$138,983
Medicare patients
328
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$48,585
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$19,158
Spiriva RespimatTiotropium Bromide11$14,690
Pramipexole DihydrochloridePramipexole Di-Hcl39$1,066
Gabapentin22$444
Albuterol Sulfate HfaAlbuterol Sulfate16$376
Clonazepam13$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$334$67,74284 claims
Boehringer IngelheimSpiriva Respimat$449$14,69011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 sleep medicine providers in Colorado.

Other sleep medicine in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →